Nature Communications (Oct 2022)
Nanoparticle-based modulation of CD4+ T cell effector and helper functions enhances adoptive immunotherapy
- Ariel Isser,
- Aliyah B. Silver,
- Hawley C. Pruitt,
- Michal Mass,
- Emma H. Elias,
- Gohta Aihara,
- Si-Sim Kang,
- Niklas Bachmann,
- Ying-Yu Chen,
- Elissa K. Leonard,
- Joan G. Bieler,
- Worarat Chaisawangwong,
- Joseph Choy,
- Sydney R. Shannon,
- Sharon Gerecht,
- Jeffrey S. Weber,
- Jamie B. Spangler,
- Jonathan P. Schneck
Affiliations
- Ariel Isser
- Department of Biomedical Engineering, Johns Hopkins University School of Medicine
- Aliyah B. Silver
- Johns Hopkins Translational ImmunoEngineering Center, Johns Hopkins University School of Medicine
- Hawley C. Pruitt
- Department of Chemical and Biomolecular Engineering, Johns Hopkins University Whiting School of Engineering
- Michal Mass
- Department of Biomedical Engineering, Johns Hopkins University School of Medicine
- Emma H. Elias
- Department of Biology, Johns Hopkins University Krieger School of Arts and Sciences
- Gohta Aihara
- Department of Biomedical Engineering, Johns Hopkins University School of Medicine
- Si-Sim Kang
- Department of Pathology, Johns Hopkins University School of Medicine
- Niklas Bachmann
- Department of Pathology, Johns Hopkins University School of Medicine
- Ying-Yu Chen
- Department of Pathology, Johns Hopkins University School of Medicine
- Elissa K. Leonard
- Department of Biomedical Engineering, Johns Hopkins University School of Medicine
- Joan G. Bieler
- Johns Hopkins Translational ImmunoEngineering Center, Johns Hopkins University School of Medicine
- Worarat Chaisawangwong
- Johns Hopkins Translational ImmunoEngineering Center, Johns Hopkins University School of Medicine
- Joseph Choy
- Johns Hopkins Translational ImmunoEngineering Center, Johns Hopkins University School of Medicine
- Sydney R. Shannon
- Department of Biomedical Engineering, Johns Hopkins University School of Medicine
- Sharon Gerecht
- Department of Biomedical Engineering, Johns Hopkins University School of Medicine
- Jeffrey S. Weber
- Laura and Isaac Perlmutter Cancer Center, NYU Langone Health
- Jamie B. Spangler
- Department of Biomedical Engineering, Johns Hopkins University School of Medicine
- Jonathan P. Schneck
- Department of Biomedical Engineering, Johns Hopkins University School of Medicine
- DOI
- https://doi.org/10.1038/s41467-022-33597-y
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 19
Abstract
Adoptive cell therapies (ACT) hold promise for cancer immunotherapy, but optimization is still an ongoing process. Here the authors report CD4-targeted, nanoparticle-based artificial antigen-presenting cells that expand CD4+ T cells capable of lysing tumor cell lysis in vitro, and CD8+ T cells showing antitumor activity in a mouse melanoma model.
